The Efficacy and Safety of Esketamine in Elective Laparoscopic Surgery
Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
The objective is to evaluate the efficacy and safety of BT-KTM-I(Esketamine Hydrochloride
Injection produced by Chengdu Brilliant Pharmaceutical Co., Ltd.) for general anesthesia,
using the Originator drug Ketanest®S(Esketamine Hydrochloride Injection) as a positive
control.